Clinical Trial Update: Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of gpASIT+TM for seasonal allergic rhinitis caused by grass pollen has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• gpASIT+TM

Snippet

Sponsor: BioTech Tools S.A. | Conditions: Grass Pollen Allergy, Hay Fever | Phase 2 | Status: COMPLETED